Probiotics-Derived Peptides and Their Immunomodulatory Molecules Can Play a Preventive Role Against Viral Diseases Including COVID-19
Authors:
- 23 November 2020
- journal article
- research article
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 13 (3) , 611-623
Abstract
As of recent, the pandemic episode of COVID-19, a severe acute respiratory syndrome brought about by a novel coronavirus (SARS-CoV-2) expanding the pace of mortality, has affected the disease rate profoundly. Invulnerability is the fundamental choice to prevent the ruining event of COVID-19, as the drugs and antibodies are in the phase of preliminary clinical trials. Within this brief period, a few strains of SARS-CoV-2 have been recognized by the vaccine manufacturers, which could be an incorrect guess about the strain that will end up spreading. Since the circulating SARS-CoV-2 strains continue to mutate, immunizations, if at all works, might be for a restricted time. We have not put sufficient time in research to understand the immune responses that correlate with protection as this could help refine vaccines. Here, we have summed up the adequacy of the immunomodulatory component of probiotics for the prevention against viral infections. Furthermore, an in silico data have been provided in support of the “probiotics-derived lipopeptides” role in inactivating spike (S) glycoprotein of SARS-CoV-2 and its host receptor molecule, ACE2. Among well characterized lipopeptides derived from different probiotic strains, subtilisin (Bacillus amyloliquefaciens), curvacin A (Lactobacillus curvatus), sakacin P (Lactobacillus sakei), lactococcin Gb (Lactococcus lactis) was utilized in this study to demonstrate a higher binding proclivity to S-protein of SARS-CoV-2 and human ACE2. The outcome revealed noteworthy capabilities of the lipopeptides, due to their amphiphilic nature, to bind spike protein and receptor molecule, which may act to competitively inhibit the mandatory interaction of SARS-CoV-2 with the host epithelial cell expressing ACE2 for its entry into the cell for reproduction. In the current situation, probiotic treatment alongside chemotherapy may assist in bringing about substantial improvement of the health of COVID-19 patients. At the same time, probiotics may aid towards building up the immune defenses in people to evade COVID-19.Keywords
This publication has 50 references indexed in Scilit:
- Microbiota Regulates the TLR7 Signaling Pathway Against Respiratory Tract Influenza A Virus InfectionCurrent Microbiology, 2013
- Inhibition of HIV and HSV infection by vaginal lactobacilli in vitro and in vivoDARU Journal of Pharmaceutical Sciences, 2012
- Regulation of Homeostasis and Inflammation in the IntestineGastroenterology, 2011
- Lactobacillus-Mediated Priming of the Respiratory Mucosa Protects against Lethal Pneumovirus InfectionThe Journal of Immunology, 2011
- Lactobacillus acidophilus induces virus immune defence genes in murine dendritic cells by a Toll‐like receptor‐2‐dependent mechanismImmunology, 2010
- Probiotic properties of non-conventional lactic acid bacteria: Immunomodulation by Oenococcus oeniInternational Journal of Food Microbiology, 2010
- Toll-like receptors as therapeutic targets in gastrointestinal diseasesExpert Opinion on Therapeutic Targets, 2010
- Validation of the dorsal air pouch model to predict and examine immunostimulatory responses in the gutJournal of Applied Microbiology, 2009
- Global trends in emerging infectious diseasesNature, 2008
- A novel eukaryotic cell culture model to study antiviral activity of potential probiotic bacteriaInternational Journal of Food Microbiology, 2007